The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
Open accessAbstract
The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with prostate-specific membrane antigen (PSMA)–positive tumor phenotype. Methods: A dosimetry estimate was calculated on the basis of time–activity curves derived from serially obtained 177Lu-PSMA-617 scans extrapolated to the physical half-life of 225Ac, assuming instant decay of unstable daughter nuclides. Salvage therapies empirically conducted with 50 (n = 4), 100 (n = 4), 150 (n = 2), and 200 kBq/kg (n = 4) of 225Ac-PSMA-617 were evaluated retrospectively regarding toxicity and treatment response. Eight of 14 patients received further cycles in either 2- or 4-mo intervals with identical or deescalated activities. Results: Dosimetry estimates for 1 MBq of 225Ac-PSMA-617 assuming a relative biologic effectiveness of 5 revealed mean doses of 2.3 Sv for salivary glands, 0.7 Sv for kidneys, and 0.05 Sv for red marrow that are composed of 99.4% α, 0.5% β, and 0.1% photon radiation, respectively. In clinical application, severe xerostomia became the dose-limiting toxicity if treatment activity exceeded 100 kBq/kg per cycle. At 100 kBq/kg, the duration of prostate-specific antigen decline was less than 4 mo, but if therapy was repeated every 2 mo patients experienced additive antitumor effects. Treatment activities of 50 kBq/kg were without toxicity but induced insufficient antitumor response in these high-tumor-burden patients. Remarkable antitumor activity by means of objective radiologic response or tumor marker decline was observed in 9 of 11 evaluable patients. Conclusion: For advanced-stage patients, a treatment activity of 100 kBq/kg of 225Ac-PSMA-617 per cycle repeated every 8 wk presents a reasonable trade-off between toxicity and biochemical response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, current clinical TAT research relies greatly on indirect approximation by extrapolating pre-existing 177Lu-labeled pharmaceuticals (84, 112, 113).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [84]
In the citing paper
“However, a low probability of γ-emission and overlapping Bremsstrahlung due to β-emitters in the 225Ac decay chain preclude simultaneous treatment and dosimetry measurement in a clinical setting (84).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
(1997) · PubMed · Cited by 1,541
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,340
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,187
Self-citationRahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M. A., Essler, M., Baum, R. P., Kulkarni, H., Schmidt, M. C., Drzezga, A. E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 861
Self-citationKratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Self-citationBenešová, M., Schäfer, M. K.-H., Bauder‐Wüst, U., Afshar‐Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147413 · Cited by 621
Self-citationGiesel, F. L., Hadaschik, B. A., Cardinale, J., Radtke, J. P., Vinsensia, M., Lehnert, W., Kesch, C. V., Tolstov, Y. L., Singer, S., Grabe, N., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3573-4 · Cited by 595
Self-citationSgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
Tumor therapy with targeted atomic nanogenerators.
McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., et al. (2001) · Science · doi:10.1126/science.1064126 · Cited by 501
Cited by
Sorted by citations
Items 301–400 of 504
Kästner, D., Hartmann, H., Freudenberg, R., Pretze, M., Brogsitter, C., Schultz, M. K., Kotzerke, J., & Michler, E. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00763-2 · Cited by 12
Metal–ligand interactions in complexes of cyclen-based ligands with Bi and Ac
Kovács, A., & Varga, Z. (2021) · Structural Chemistry · doi:10.1007/s11224-021-01816-9 · Cited by 12
Oh, S. W., Suh, M., & Cheon, G. J. (2022) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-022-00764-4 · Cited by 12
Modeling the effect of daughter migration on dosimetry estimates for unlabeled actinium‐225
Tronchin, S., Forster, J. C., Hickson, K., & Bezak, E. (2024) · Medical Physics · doi:10.1002/mp.16917 · Cited by 12
Du, Y., Cortez, A. G., Josefsson, A., Zarisfi, M., Krimins, R. A., Liapi, E. A., & Nedrow, J. R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261982 · Cited by 12
Emerging Therapeutic Radiopharmaceuticals and Their Theranostic Pairs
Carbo‐Bague, I., & Ramogida, C. F. (2021) · Wiley eBooks · doi:10.1002/9781119951438.eibc2763 · Cited by 12
Prostate Cancer Radioligand Therapy
Yechiel, Y., Chicheportiche, A., Keidar, Z., & Ben‐Haim, S. (2024) · PET Clinics · doi:10.1016/j.cpet.2024.03.011 · Cited by 11
Tan, C., Cao, S., Gao, R., Wang, J., Tian, W., Huang, Q., Chen, D., Lin, M., Li, B., Wu, X., et al. (2024) · Separation and Purification Technology · doi:10.1016/j.seppur.2024.129371 · Cited by 11
Theranostics Advances in the Treatment and Diagnosis of Neurological and Neurosurgical Diseases
Awuah, W. A., Ahluwalia, A., Tan, J. K., Sanker, V., Roy, S., Ben-Jaafar, A., Shah, D. M., Tenkorang, P. O., Aderinto, N., Abdul-Rahman, T., et al. (2024) · Archives of Medical Research · doi:10.1016/j.arcmed.2024.103085 · Cited by 11
Baimukhanova, A., Engudar, G., Marinov, G., Kurakina, E. S., Dadakhanov, J. A., Karaivanov, D., Yang, H., Ramogida, C. F., Schaffer, P. C., Magomedbekov, E. P., et al. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.06.003 · Cited by 11
In vivo quantitative SPECT imaging of actinium-226: feasibility and proof-of-concept
Koniar, H., Wharton, L., Ingham, A., Rodríguez‐Rodríguez, C., Kunz, P., Radchenko, V., Yang, H., Rahmim, A., Uribe, C., & Schaffer, P. C. (2024) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ad5c37 · Cited by 11
Denis-Bacelar, A. M., Chittenden, S. J., McCready, V. R., Divoli, A., Dearnaley, D. P., O’Sullivan, J. M., Johnson, B., & Flux, G. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170795 · Cited by 11
Sheikh, G. T., Delker, A., Zacherl, M. J., Holzgreve, A., Fouladgar, S. T., Unterrainer, M., Rübenthaler, J., Casuscelli, J., Gafita, A., & Unterrainer, L. M. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01211-z · Cited by 10
Prostate-specific membrane antigen radioligand therapy of prostate cancer
Beheshti, M., Heinzel, A., von Mallek, D., Filß, C., & Mottaghy, F. M. (2019) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.19.03155-8 · Cited by 10
Parent, E. E., & Kase, A. M. (2022) · Cancers · doi:10.3390/cancers14174276 · Cited by 11
Nakajima, R. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c23-00535 · Cited by 10
Mohan, V., Bruin, N. M., Tesselaar, M. E. T., de Boer, J. P., Vegt, E., Hendrikx, J. J. M. A., Al‐Mamgani, A., van de Kamer, J. B., Sonke, J., & Vogel, W. V. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00770-1 · Cited by 10
Nava-Cabrera, M. A., Azorin‐Vega, E. P., Oros‐Pantoja, R., & Aranda‐Lara, L. (2021) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2021.109898 · Cited by 10
Mechanistic Modeling of Radium-223 Treatment of Bone Metastases
Moreira, H., Liberal, F. D. C. G., O’Sullivan, J. M., McMahon, S. J., & Prise, K. M. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.12.015 · Cited by 11
Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics
Eshghi, A., Covington, M. F., Eshghi, N., & Kuo, P. H. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004196 · Cited by 10
Huang, S. S.-L., DiFilippo, F. P., Lindner, D. J., & Heston, W. D. W. (2024) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-024-00237-3 · Cited by 9
Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies
Mallak, N., Yılmaz, B., Meyer, C. A. L., Winters, C., Mench, A. M., Jha, A. K., Prasad, V., & Mittra, E. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101129 · Cited by 9
Astatine-211 and actinium-225: two promising nuclides in targeted alpha therapy
Zuo, D., Wang, H. Z., Yu, B., Li, H., Gan, L., & Chen, W. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024206 · Cited by 10
Tomiyoshi, K., Wilson, L. J., Mourtada, F., Sims‐Mourtada, J., Namiki, Y., Kamata, W., Yang, D. J., & Inoue, T. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111458 · Cited by 9
Vilangattil, M. M., Swaidan, A., Godinez, J., Taddio, M. F., Czernin, J. G., Mona, C. E., & Carlucci, G. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00333-y · Cited by 9
Fibroblast Activation Protein-Targeted Theranostics: Current Status in Clinical Development
Kang, Y.-K. (2025) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-025-00935-z · Cited by 9
Wurzer, A. J., Sun, B., Saleh, S., Brosch-Lenz, J., Fischer, S., Kossatz, S., Hürkamp, K., Li, W. B., Eiber, M., Morgenstern, A., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.269744 · Cited by 9
Self-citationAdvances in Dosimetry and Imaging for 203Pb and 212Pb Radiotheranostics
Ramonaheng, K., Qebetu, M., Banda, K., Goorhoo, P., Legodi, K., Mdanda, S., Sibiya, S. M., Mzizi, Y. V., Ndlovu, H., Kabunda, J., et al. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.09.006 · Cited by 9
Iorio, V. D., Sarnelli, A., Boschi, S., Sansovini, M., Genovese, R. M., Ştefănescu, C., Ghizdovăţ, V., Jalloul, W., Young, J. D., Sosabowski, J. K., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18101578 · Cited by 10
Chen, J., Qi, L., Tang, Y., Tang, G., Gan, Y., & Cai, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.958180 · Cited by 9
USE OF 177Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
Medvedeva, A. А., Чернов, В. И., Usynin, E. A., Zelchan, R., Bragina, O., & Lushnikova, N. A. (2021) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2021-20-3-115-123 · Cited by 9
177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements
Cao, J., Chen, Y., Hu, M. L., & Zhang, W. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01649-w · Cited by 9
225Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy
Rosar, F., Burgard, C., Rohloff, L. V., Blickle, A., Bartholomä, M. D., Maus, S., Petto, S., Schaefer-Schuler, A., & Ezziddin, S. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005253 · Cited by 9
Göring, L., Schumann, S., Müller, J., Buck, A. K., Port, M., Laßmann, M., Scherthan, H., & Eberlein, U. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05860-3 · Cited by 9
Oroujeni, M., Abouzayed, A., Lundmark, F., Mitran, B., Orlova, A., Максимилианович, Т. В., & Rosenström, U. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11080380 · Cited by 9
Prodrugs Targeting Prostate-Specific Membrane Antigen against Prostate Cancer
Liolios, C. C., Laros, G., Georgiou, K., & Kolocouris, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02626 · Cited by 8
Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma
Wale, D. J., Viglianti, B. L., Gross, M. D., Ferretti, A., Rubello, D., & Wong, K. K. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000479 · Cited by 8
Advanced prostate cancer update 2018
Sartor, O. A. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13057 · Cited by 8
Civelek, A. C. (2026) · Cancers · doi:10.3390/cancers18020234 · Cited by 7
Clinical Image-Based Dosimetry of Actinium-225 in Targeted Alpha Therapy
Ramonaheng, K., Banda, K., Qebetu, M., Goorhoo, P., Legodi, K., Masogo, T., Seebarruth, Y., Mdanda, S., Sibiya, S. M., Mzizi, Y. V., et al. (2026) · Cancers · doi:10.3390/cancers18020321 · Cited by 8
JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging
Nedelcovych, M. T., Dash, R. P., Wu, Y., Choi, E. Y., Lapidus, R. S., Majer, P., Jančařík, A., Abou, D. S., Penet, M., Nikolopoulou, A., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07044-7 · Cited by 7
Self-citationOyen, W. J. G., & Bono, J. S. D. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.179887 · Cited by 7
Haberkorn, U., Kratochwil, C., Mamlins, E., Mori, Y., & Giesel, F. L. (2020) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-42618-7_29 · Cited by 7
Self-citationKnow thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy
O’Neill, E. S., & Cornelissen, B. T. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.02.004 · Cited by 7
Milenic, D. E., Baidoo, K. E., Kim, Y., Barkley, R., & Brechbiel, M. W. (2017) · Dalton Transactions · doi:10.1039/c7dt01819c · Cited by 7
In silico assessment of cellular damage from Lu‐177, Ac‐225, and Pb‐212 therapeutic radionuclides
Chatzipapas, K., Papachristou, K., Visvikis, D., Incerti, S., Hazle, J. D., & Kagadis, G. C. (2025) · Medical Physics · doi:10.1002/mp.70089 · Cited by 6
Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals
Ndlovu, H., Mokoala, K. M. G., Lawal, I. O., Emmett, L., & Sathekge, M. M. (2024) · PET Clinics · doi:10.1016/j.cpet.2024.03.003 · Cited by 6
Adverse reactions to therapeutic radiopharmaceuticals
Silindir‐Gunay, M., & Ozolmez, N. (2024) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2024.111527 · Cited by 6
Production and purification of molecular 225Ac at CERN-ISOLDE
Au, M., Nies, L., Stegemann, S., Athanasakis-Kaklamanakis, M., Cocolios, T. E., Fischer, P., Giesel, P. F., Johnson, J. D., Köster, U., Lange, D., et al. (2024) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-024-09811-0 · Cited by 8
Bordes, J., Incerti, S., Mora‐Ramirez, E., Tranel, J., Rossi, C., Bezombes, C., Bordenave, J., Bardiès, M., Brown, R., & Bordage, M. (2020) · Medical Physics · doi:10.1002/mp.14370 · Cited by 6
Kovács, A., & Varga, Z. (2021) · Structural Chemistry · doi:10.1007/s11224-020-01717-3 · Cited by 6
Theoretical Study of Complexes of Tetravalent Actinides with DOTA
Kovács, A. (2022) · Symmetry · doi:10.3390/sym14112451 · Cited by 6
Rahman, M. A., Li, Z., Yu, Z., Laforest, R. A., Thorek, D. L. J., & Jha, A. K. (2023) · EJNMMI Physics · doi:10.1186/s40658-023-00558-3 · Cited by 6
Ong, W. M., Zargar‐Shoshtari, K., Siva, S., & Zargar, H. S. (2018) · Minerva Urologica e Nefrologica · doi:10.23736/s0393-2249.18.03152-1 · Cited by 6
Suthiram, J., Pieters, A., Mohamed-Moosa, Z., Zeevaart, J. R., Sathekge, M. M., Ebenhan, T., Anderson, R. C., & Newton, C. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032134 · Cited by 6
Radiolabeled Protein-inhibitor Peptides with Rapid Clinical Translation towards Imaging and Therapy
Ferro‐Flores, G., Ocampo‐García, B., Luna‐Gutiérrez, M., Santos‐Cuevas, C., Jiménez‐Mancilla, N., Azorin‐Vega, E. P., & Meléndez‐Alafort, L. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867327666191223121211 · Cited by 6
Hadaschik, B. A., & Boegemann, M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.194753 · Cited by 6
JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted RadiotherapyPreprint
Nedelcovych, M. T., Dash, R. P., Wu, Y., Choi, E. Y., Lapidus, R. S., Majer, P., Abou, D. S., Penet, M., Nikolopoulou, A., Amor-Coarasa, A., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/457085 · Cited by 6
Self-citationRecent Trends in Radiopharmaceuticals: Focused on Drug Delivery to the Targeted Tissues
Ito, T., Hachisuka, A., Ishii‐Watabe, A., Saito, Y., Demizu, Y., & Misawa, T. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00407 · Cited by 5
Click Covalent-Targeted Radionuclide Therapy for Prostate Cancer
Yong, W. P., Zhang, S., Zhang, Z., Li, Z., Qin, Y., Qi, X., Wang, D., Zhang, Y., Li, J., Liu, Z., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01515 · Cited by 5
EANM recommendations for dosimetry in targeted radionuclide therapy with alpha-emitters
Gabiña, P. M., Gleisner, K. S., Chouin, N., Tran‐Gia, J., Koole, M., Cremonesi, M., Denis-Bacelar, A. M., Cassano, B., Verburg, F. A., Brosch-Lenz, J., et al. (2026) · EANM Innovation · doi:10.1016/j.eanmi.2025.100018 · Cited by 6
Ventura, D., Noto, B., Jauregui, N. R., Roll, W., & Rahbar, K. (2025) · Current Opinion in Urology · doi:10.1097/mou.0000000000001300 · Cited by 5
Modeling the Effect of Daughter Migration on Dosimetry Estimates for [225Ac]Ac-DOTATATE
Tronchin, S., Forster, J. C., Hickson, K., & Bezak, E. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.03.004 · Cited by 5
Functional Optimization of Radionuclide Pairs in Theranostics of Prostate Cancer
Narkevich, B. Y., Dolgushin, M. B., Крылов, В. В., Meshcheryakova, N. A., & Невзоров, Д. И. (2020) · Journal of oncology diagnostic radiology and radiotherapy · doi:10.37174/2587-7593-2020-3-1-38-56 · Cited by 5
Synthesis of 225Ac-PSMA-617 for Preclinical Use
Scott, P. J. H., Sowa, A. R., Rodnick, M. E., & Piert, M. (2021) · Current Radiopharmaceuticals · doi:10.2174/1874471014666210709094616 · Cited by 5
Goodacre, T. D., Billowes, J., Binnersley, C. L., Bissell, M. L., Chrysalidis, K., Cocolios, T. E., de Groote, R. P., Farooq-Smith, G. J., Федоров, Д. В., Fedosseev, V. N., et al. (2018) · Spectrochimica Acta Part B Atomic Spectroscopy · doi:10.1016/j.sab.2018.10.002 · Cited by 5
The effect of eating on the uptake of PSMA ligands in the salivary glands
Mohan, V., Bruin, N. M., van de Kamer, J. B., Sonke, J., & Vogel, W. V. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00838-y · Cited by 5
Value proposition of PSMA-targeted α–particle radioligand therapy in metastatic prostate cancer
Jadvar, H. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4191-0 · Cited by 5
Radiopharmaceuticals in Oncology
Goos, J. A. C. M., Keinänen, O. M., Zeglis, B. M., & Lewis, J. S. (2020) · Wiley eBooks · doi:10.1002/9781119500575.ch18 · Cited by 5
Hu, Z., Qu, S., Liu, H., Zhang, Y., Yan, S., Hu, A., Qiu, R., Wu, Z., Zhang, H., & Li, J. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00765-0 · Cited by 4
Navigating the safety profile of Actinium-225 targeted alpha therapy: a comprehensive review
Roustaei, H., D’Alessandria, C., & Decristoforo, C. (2025) · Clinical and Translational Imaging · doi:10.1007/s40336-025-00733-9 · Cited by 4
Feasibility study of 225Ac-PSMA-CY313 dosimetry in mCRPC patients using SPECT
Zhang, H., Shi, Y., Tang, H., Gu, H., Luo, F., Daiyuan, M., Tang, T., & Li, S. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00831-7 · Cited by 4
Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective
Maithania, H. V., John, R., Painoori, R., monpara, J., Swaminathan, S., & Kalhapure, R. S. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03346-1 · Cited by 4
Targeted α therapy with 213Bi and 225Ac
Kellerbauer, A., Bruchertseifer, F., Malmbeck, R., & Morgenstern, A. (2020) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1643/1/012205 · Cited by 4
Self-citationA molten salt test loop for component and instrumentation testing
Head, T., Berry, A. M., Brewster, K. J., Brown, R. L., Burden, H. N., Byrd, R., Doty, T., Dowdy, J., Hill, K. A., Jinkerson, R. A., et al. (2023) · Annals of Nuclear Energy · doi:10.1016/j.anucene.2023.109772 · Cited by 4
Yamamichi, G., Kato, T., Watabe, T., Hatano, K., Uemura, M., & Nonomura, N. (2024) · Anticancer Research · doi:10.21873/anticanres.16881 · Cited by 5
Aurilio, M., Esposito, A., Buonanno, M. J., Morisco, A., Maisto, C., Scala, S., & Lastoria, S. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00344-9 · Cited by 4
[177Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?
Paganelli, G., & Giorgi, U. D. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30268-7 · Cited by 4
van der Sar, E. C. A., de Keizer, B., Lam, M. G. E. H., & Braat, A. J. A. T. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050699 · Cited by 4
Maystrenko, D. N., Stanzhevskii, A. A., Важенина, Д. А., Одинцова, М. В., Попов, С. А., Номоконова, В. Б., Чипига, Л. А., Сапрыкин, К. А., Gromov, A. V., & Vasiliev, S. K. (2023) · Diagnostic radiology and radiotherapy · doi:10.22328/2079-5343-2022-13-4-86-94 · Cited by 4
Petrova, A. E., Чипига, Л. А., Водоватов, А. В., Stanzhevsky, A. A., Maystrenko, D. N., Lumpov, A. A., Sinyukhin, A. B., Boykov, I. V., & Rameshvili, T. E. (2022) · Radiacionnaâ gigiena · doi:10.21514/1998-426x-2022-15-1-120-131 · Cited by 4
Kochetova, T. Y., Крылов, В. В., Sigov, M. A., Ripp, V. O., Shurinov, A. Y., Vasiliev, K. G., Legkodimova, N. S., Иванов, С. А., & Каприн, А. Д. (2024) · Journal of oncology diagnostic radiology and radiotherapy · doi:10.37174/2587-7593-2024-7-1-30-40 · Cited by 4
Cytawa, W., Hartrampf, P. E., Lass, P., Kircher, M., Polat, B., Buck, A. K., & Lapa, C. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.03.008 · Cited by 4
Theranostics in Metastatic Castrate Resistant Prostate Cancer
Vorster, M., & Sathekge, M. M. (2021) · Exon Publications eBooks · doi:10.36255/exonpublications.prostatecancer.theranostics.2021 · Cited by 4
225Aс-PSMA-617 therapy in metastatic castration-resistant prostate cancer
Kochetova, T. Y., Крылов, В. В., Иванов, С. А., & Каприн, А. Д. (2025) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2024-23-6-32-40 · Cited by 3
Abdlkadir, A. S., Al-Adhami, D. A., Moghrabi, S., Sathekge, M. M., Kreissl, M. C., Estrada-Lobato, E., Shi, H., & Al‐Ibraheem, A. (2026) · BMC Cancer · doi:10.1186/s12885-026-15900-y · Cited by 3
In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with 225Ac
Fialová, K. O., Ondrák, L., Vlk, M., Kozempel, J., Nováková, K., Nový, Z., Hajduová, K., Hajdúch, M., Petřík, M., Pruszyński, M., et al. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00337-8 · Cited by 3
Self-citationHuang, E., Steffen, I. G., Lukas, M., Huang, K., Aschenbach, J. R., Eary, J. F., Brenner, W., & Beindorff, N. (2019) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-0810-0174 · Cited by 3
Pistone, D., Gnesin, S., Auditore, L., Italiano, A., Cascini, G. L., Amato, E., & Cicone, F. (2023) · Physics in Medicine and Biology · doi:10.1088/1361-6560/acc633 · Cited by 3
Quantitative and Computational Radiobiology for Precision Radiopharmaceutical Therapies
Yusufaly, T., Abdollahi, H., Saboury, B., & Rahmim, A. (2025) · PET Clinics · doi:10.1016/j.cpet.2025.08.005 · Cited by 3
Dispersion of Alpha-Nuclides during Animal Experiments
Kaneda‐Nakashima, K., Zhang, Z., Nagata, K., Shirasaki, K., Kikunaga, H., YAMAMURA, T., Ooe, K., Watabe, T., Toyoshima, A., Yoshimura, T., et al. (2021) · Radiation Safety Management · doi:10.12950/rsm.210519 · Cited by 3
Radiation nephropathy: Dose, management, and population risk
Cohen, E. P., Premuzic, T., & Cohen, A. P. (2021) · Journal of Onco-Nephrology · doi:10.1177/23993693211064065 · Cited by 3
Rojas, J. V., Umretiya, R. V., Higgins, M. C. M., Ermi, A. G., Sundaresan, G., & Zweit, J. (2022) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2022.110296 · Cited by 3
Giraudet, A. (2019) · Médecine Nucléaire · doi:10.1016/j.mednuc.2019.03.003 · Cited by 3
Schacherl, B., Maurer, K., Schäfer, M. K.-H., Remde, Y., Geyer, F., Fried, A., Happel, S., & Benešová, M. (2024) · Frontiers in Nuclear Engineering · doi:10.3389/fnuen.2024.1379996 · Cited by 2
Lutetium-177 Theranostics and Dosimetry for Neuroendocrine Neoplasms and Prostate Cancer
Wong, K. K., Hu, E. M., Akhavanallaf, A., Dewaraja, Y. K., & Roseland, M. E. (2025) · Seminars in Roentgenology · doi:10.1053/j.ro.2025.04.005 · Cited by 2
Liubchenko, G., Böning, G., Rumiantcev, M., Zounek, A. J., Zacherl, M. J., Sheikh, G. T., Resch, S., Werner, R. A., Ziegler, S. I., & Delker, A. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00800-0 · Cited by 2
Clinical perspective on targeted alpha therapy using 225Ac
Lim, I. (2025) · Annals of Nuclear Medicine · doi:10.1007/s12149-025-02117-5 · Cited by 2
Dewulf, J., Navarro, L., Dumauthioz, N., Berdal, M., Nagachinta, S., Gaspariunaite, V., Antunes, A. R. P., Lahoutte, T., Massa, S., Devoogdt, N., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07572-2 · Cited by 2
Naka, S., Tadashi, W., Shirakami, Y., Ooe, K., Kurimoto, K., Sakai, T., Toyoshima, A., Murakami, M., Kon, Y., Haba, H., et al. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00416-w · Cited by 2
Self-citation
Metadata
- Authors
- Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A.
- Affiliations
- University Hospital Heidelberg (DE)
- European Commission (BE)
- ABX-CRO Advanced Pharmaceutical Services (Germany) (DE)
- Pathologisches Institut (DE)
- German Cancer Research Center (DE)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2017-04-13
- Volume
- 58
- Issue
- 10
- Pages
- 1624-1631
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2606187374
- Cited by
- 505
- References
- 31
- Citations by year
- 2026: 35 · 2025: 60 · 2024: 48 · 2023: 36 · 2022: 53 · 2021: 83 · 2020: 57 · 2019: 61 · 2018: 57 · 2017: 14
- FWCI
- 39.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Joint Research Centre (European Commission) (submittedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- metastatic castration-resistant prostate cancer, dosimetry, 177Lu-PSMA-617, xerostomia, salvage therapy, PSA response, treatment toxicity
- MeSH terms
- Actinium, Aged, Alpha Particles, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Male, Middle Aged, Neoplasm Metastasis, Radiometry, Radiotherapy Dosage, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
